참고문헌 (24)

1. Baek SM, Ko SJ, Kim CS, Kim JH, Kang SS. A Study on Ways to Optimize the Period of Hospitaliztion During High-Dose I-131 Treatment of the Thyroid Cancer. Journal of Radiological Science and Technology. 2010;33(3):269-76. 

2. Andresen NS, Buatti JM, Tewfik HH, Pagedar NA, Anderson CM, Watkins JM. Radioiodine ablation following thyroidectomy for differentiated thyroid cancer: Literature review of utility, dose, and toxicity. European Thyroid Journal. 2017;6(4):187-96. 

   상세보기

3. Lahfi Y, Anjak O. Evaluation of the release criteria from hospital of thyroid carcinoma patient treated with 131I. Radiation Protection Dosimetry. 2016;(4):534-8. 

4. Abu-Khaled Y, Sandouqa A, Haddadin I. Radiation exposure from radioactive iodine I-131 in and surrounding the patients' room. Radiation Protection Dosimetry. 2009;135(1):64-8. 

   상세보기

5. Agency IAE. Release of Patients After Radionuclide Therapy, with Contributions from the International Commission on Radiological Protection. International Atomic Energy Agency; 2009. 

6. Radioactivity MSC-oPitMoPWHRTAo. Management of radionuclide therapy patients. NCRP; 2007. 

7. Howe DB, Beardsley M, Bakhsh S. Consolidated guidance about materials licenses. Program-Specific Guidance About Medical Use Licenses (NUREG-1556, volume 9, revision 2); 2008. 

8. Nuclear Safety Commission No. 19 Regulations on Technical Standards such as Radiation Safety Management. Nuclear Safety Commission Notification No. 2015-5 Technical Standards on Radiation Safety Management in the Medical Sector. 

9. Jeong GH, Lee HK, Cho WK, Lee JK. Caregiver or Family Doses due to Discharged I-131 Administrated Patient from the Hospital. Journal of Radiological Science and Technology. 2010;33(2):149-54. 

10. Valentin J, Boice Jr. J, Clarke R, Cousins C, Gonzalez A, Lee J, et al. Published on behalf of International Commission on Radiological Protection. ICRP Publication; 2007. 

11. Schneider S, McGuire SA, Behling U, Behling K, Goldin D. Regulatory analysis on criteria for the release of patients administered radioactive material. Nuclear Regulatory Commission; 1994. 

12. Kadhim AA, Sheikhzadeh P, Farzanefar S, Yavari S, Ay MR. Radiation Dose Assessment to Family Members Taking Care of Non-Cancerous Thyroid Patients Treated with I-131 Therapy in Nuclear Medicine Department. Radiation Protection Dosimetry. 2020;190(2):208-16. 

    상세보기

13. Ebrahimi M, Changizi V, Kardan MR, Pooya SMH, Geramifar P. Experimental and analytical dose assessment of patient's family members treated with I-131. Phys Med. 2016;3(32):292. 

14. Moon YM. A study on the effective dose measurement for cone beam computed tomography using glass dosimeter. Graduate School, Dong-A University; 2013. 

15. Kang IS, Ahn SM. Evaluation of Usability and Radiation Dose Measurement Using Personal Radiation Exposure Dosimeter. International Journal of Contents. 2014;14(11):864-870. 

16. Taghavaee S, Kasesaz Y, Barough MS. Analysis of the caregiver effective dose during I-131 therapy of thyroid. Journal of Cancer Research and Therapeutics. 2018;14(6):1361. 

    상세보기

17. Director M, Chief B, Director A, Date S, Date A. Office of Federal and State Materials and Environmental Management Programs (FSME) Procedure Approval Reviewing the Non-Common Performance Indicator. Uranium Recovery Program-SA-110; 2009. 

18. De Carvalho JWdA, Sapienza M, Ono C, Watanabe T, Guimaraes MI, Gutterres R, et al. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (I-131) Nal, on an outpatient basis, be safe? Nuclear Medicine Communications. 2009;30(7):533-41. 

    상세보기

19. Park SG. Effective half-life of I-131 in patients with differentiated thyroid cancer treated by radioactive I-131. Nuclear Medicine and Molecular Imaging. 2008;42(6):464-8. 

20. Gringsby PW, Siegel BA, Baker S, Eichling JO. Radiation exposure from outpatient radioactiveiodine (I-131) therapy for thyroid carcinoma. Jama. 2000;283(17):2272-4. 

    상세보기

21. Marriott CJ, Webber CE, Gulenchyn KY. Radiation exposure for 'caregivers' during high-dose outpatient radioiodine therapy. Radiation Protection Dosimetry. 2017;123(1):62-7. 

    상세보기

22. Commission UNR. Release of individuals containing unsealed byproduct material or implants containing byproduct material. Washington, DC: US Nuclear Regulatory Commission.10; 2017. 

23. Hennessey JV, Parker JA, Kennedy R, Garber JR. Comments regarding Practice Recommendations of the American Thyroid Association for radiation safety in the treatment of thyroid disease with radioiodine. Thyroid. 2012;22(3):336-7. 

    상세보기

24. Sisson TATATRSJC, Freitas J, McDougall IR, Dauer LT, Hurley JR, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: Practice recommendations of the American Thyroid Association. Thyroid. 2011;21(4):335-46. 

    상세보기